Xenetic Biosciences Q1 2024 GAAP EPS $(0.78) Beats $(0.79) Estimate, Sales $510.817K Miss $650.000K Estimate
Portfolio Pulse from Benzinga Newsdesk
Xenetic Biosciences (NASDAQ:XBIO) reported Q1 2024 GAAP EPS of $(0.78), slightly beating the $(0.79) estimate. However, their sales of $510.817K fell short of the $650.000K estimate, marking a 15.69% decrease from the previous year.
May 10, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Xenetic Biosciences reported a mixed Q1 2024 with an EPS beat but significant sales miss and year-over-year decline.
The slight EPS beat may provide some positive sentiment, but the significant miss on sales and the year-over-year decline are likely to concern investors, potentially leading to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100